Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 6/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19942357 | 0.80 | KDM4E (0.30) | KDM4ENPSR1 | |
| SCHEMBL19939393 | 0.70 | RXFP1 (0.39) | SMN1; SMN2 | |
| SCHEMBL18223396 | 0.67 | PDE10A (0.38) | PDE10AKDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL19942422 | 0.67 | DPP4 (0.31) | — | |
| SCHEMBL3021727 | 0.64 | PDE10A (0.34) | PDE10AALDH1A1 | |
| SCHEMBL21266716 | 0.64 | XDH (0.30) | POLB | |
| SCHEMBL10309386 | 0.62 | PDE10A (0.47) | PDE10A | |
| SCHEMBL12415261 | 0.62 | ALDH1A1 (0.49) | PDE10AKDM4EALDH1A1SMN1; SMN2NPSR1 | |
| SCHEMBL3010826 | 0.62 | PDE10A (0.36) | PDE10AALDH1A1SMN1; SMN2 | |
| SCHEMBL19942292 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11731977-B2 | SGC stimulators | CYCLERION THERAPEUTICS, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-20180065971-A1 | sGC STIMULATORS | TISENTO THERAPEUTICS INC. | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180065971-A1 | sGC STIMULATORS | GUCY1A2, PRKG1, GMPS | PDE10A 17/4885KDM4E 3250/4885ALDH1A1 2650/4885 |
| US-11731977-B2 | SGC stimulators | GUCY1A2, PRKG1, GMPS | PDE10A 17/4885KDM4E 3250/4885ALDH1A1 2650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.